Free Trial
NASDAQ:TERN

Terns Pharmaceuticals Q2 2023 Earnings Report

Terns Pharmaceuticals logo
$2.40 +0.17 (+7.37%)
Closing price 04/17/2025 03:59 PM Eastern
Extended Trading
$2.48 +0.08 (+3.33%)
As of 04/17/2025 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Terns Pharmaceuticals EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Terns Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Terns Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Tuesday, August 8, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Terns Pharmaceuticals' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Terns Pharmaceuticals Earnings Headlines

Terns Pharmaceuticals management to meet with Oppenheimer
Musk’s AI Masterplan – Our #1 AI Stock to Buy Now
Did Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so. Musk has been quietly creating one of the most ambitious AI ventures in history.
Oppenheimer Remains a Buy on Terns Pharmaceuticals (TERN)
See More Terns Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Terns Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Terns Pharmaceuticals and other key companies, straight to your email.

About Terns Pharmaceuticals

Terns Pharmaceuticals (NASDAQ:TERN), a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

View Terns Pharmaceuticals Profile

More Earnings Resources from MarketBeat